Karolinska Development - Interim report January - September, conference call Friday, November 25

21 november 2011 STOCKHOLM - November 21, 2011. Karolinska Development will publish its interim report for January - September 2011 at 08.30 CET on Friday, November 25. The company will also host a conference call on the same day at 14.00 CET. Participant access numbers: +46 (0)8 505 598 12, UK: +44 (0)20 710 862 05. Hosts: Torbjörn Bjerke, CEO, and Gunnar Casserstedt, CFO. For further information, please contact: Benjamin Nordin, IR Director, Karolinska Development Phone: +46 (0)73 093 60 80, e-mail: benjamin.nordin@karolinskadevelopment.com TO THE EDITORS About Karolinska Development Karolinska Development aims to create value for investors, patients, and researchers by developing innovations from world class research into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP these to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out licensing of products. This will result in upfront payments, milestone payments and royalties. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading Nordic universities, delivers a continuous flow of innovations. Karolinska Development's flexible exit strategy enables projects to be exited at whichever stage of development offers the greatest return on investment, usually after Phase II clinical trials have indicated the desired pharmaceutical effect on patients - this being an important value enhancing step. Today, the portfolio consists of over 35 projects at various stages, from concept development to Phase II clinical trials, twelve projects are in clinical trials. The portfolio is particularly strong in the areas of cancer, dermatology, inflammation, cardiovascular disease, women's health and diseases that affect the central nervous system. For more information, see www.karolinskadevelopment.com Press Release as PDF: http://hugin.info/143071/R/1565278/485749.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Karolinska Development AB (publ) via Thomson Reuters ONE [HUG#1565278]